



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

JPL/SEC/RESU-NOT1

Date : May 30th, 2014

The National Stock Exchange of India Limited
Kind Attn. Mr. Hari K. - Vice President
Exchange Plaza, Bandra-Kurla Complex
Bandra E), Mumbai - 400 051.
FAX 022-26598237-38

The Bombay Stock Exchange Limited
Pherozebhoj Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
FAX 022-22723121, 22722037, 22723719, 22722041

SUB: AUDITED FINANCIAL RESULTS FOR QUARTER/YEAR ENDED 31.03.2014 & AUDITOR REPORT ON FINANCIAL RESULTS.

Dear Sir,

In terms of Clause 41 of the listing agreement we are sending herewith audited financial results for the quarter/year ended 31st March, 2014 and Auditor's Report on Financial Results..

Thanking you.

Yours faithfully,
for **JAGSONPAL PHARMACEUTICALS LIMITED**


R K KAPOOR
COMPLIANCE OFFICER CUM COMPANY SECRETARY



Encl. : As above.



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

Audited Financial Results for the Quarter ended 31.03.2014

		Rs. in lacs			
PART-I					
Particulars	3 months ended 31.03.2014 Audited	3 months ended 31.12.2013 Unaudited	3 months ended 31.03.2013 Audited	12 Months ended 31.03.2014 Audited	12 Months ended 31.03.2013 Audited
1 Income from operations					
a Net sales/Income from Operations (Net of excise duty)	3128.08	3770.16	3813.31	14385.09	16646.45
b Other Operating Income					
Total Income from operations (net)	3128.08	3770.16	3813.31	14385.09	16646.45
2 Expenses					
a Cost of materials consumed	1047.14	1457.69	1327.06	5461.64	7091.87
b Purchases of stock-in-trade	565.48	305.49	207.49	1294.90	1069.51
c Changes in inventories of finished goods,	-939.18	132.96	612.47	-285.94	454.84
d Employee benefits expenses	1022.02	913.54	912.47	3783.43	3725.46
e Depreciation and amortisation expense	68.51	73.90	64.63	282.54	270.76
f Other expenses	1061.74	660.96	572.86	3063.27	3299.35
Total expenses	2825.71	3544.54	3696.98	13599.84	15911.79
3 Profit from Operations before Other Income, Finance Cost and Exceptional	302.37	225.62	116.33	785.25	734.66
4 Other Income	6.07		32.31	6.07	32.31
5 Profit from ordinary activities before finance cost and Exceptional items (3+4)	308.44	225.62	148.64	791.32	766.97
6 Finance Cost	183.16	108.22	140.42	538.19	513.35
7 Profit from ordinary activities after finance cost but before Exceptional items (5-6)	125.28	117.40	8.22	253.13	253.62
8 Exceptional Items					
9 Profit/(+)/Loss(-) from Ordinary Activities before tax (7+8)	125.28	117.40	8.22	253.13	253.62
10 Tax expense	3.08	28.48	-24.64	41.06	70.36
11 Net Profit/Loss(-) from Ordinary Activities after tax (9-10)	122.20	88.92	32.86	212.07	183.26
12 Extraordinary Items (net of tax expense Rs. lacs)					
13 Net Profit/(+)/Loss(-) for the period(11-12)	122.20	88.92	32.86	212.07	183.26
14 Share of profit/(Loss) of associates					
15 Minority interest					
16 Net Profit/(Loss) after taxes, minority	122.20	88.92	32.86	212.07	183.26
17 Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90
18 Reserves excluding Revaluation reserves as per Balance sheet of pr. Accounting yr				7298.31	7239.49
19.i Earnings Per Share (before extraordinary items)					
a. Basic (Rs.)	0.47	0.34	0.13	0.81	0.70
b. Diluted (Rs.)	0.47	0.34	0.13	0.81	0.70
19.ii Earnings Per Share (after extraordinary items)					
a. Basic (Rs.)	0.47	0.34	0.13	0.81	0.70
b. Diluted (Rs.)	0.47	0.34	0.13	0.81	0.70
PART-II					
A PARTICULARS OF SHAREHOLDING					
1 Public Shareholding					
- Number of shares	8962360	8962360	8962360	8962360	8962360
- Percentage of Shareholding	34.21%	34.21%	34.21%	34.21%	34.21%
2 Promoter and promoter group shareholding					
A Pledged / encumbered					
- Number of shares					
- Percentage of shares (as a % of the total shareholding of Promoter and promoter					
- Percentage of shares (as a % of the total share capital of the Company)					
B Non - encumbered					
- Number of shares	17235640	17235640	17235640	17235640	17235640
- Percentage of shares (as a % of the total shareholding of Promoter and promoter	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the Company)	65.79%	65.79%	65.79%	65.79%	65.79%
B INVESTOR COMPLAINTS					
Pending at the beginning of the quarter	0	0	0		
Received during the quarter	40	18	39		
Disposed of during the quarter	40	18	39		
Remaining unresolved at the end of the	0	0	0		

Notes

- The Audited Financial Results for the Quarter ended 31.03.2014 have been reviewed by the Audit Committee. The Board of Directors has approved the financial Results at its meeting held on 30.05.2014
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
- Previous year figures have been regrouped / rearranged wherever necessary.

By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Place : New Delhi
Date : 30.05.2014

Rajpal Singh Kochhar
Managing Director

Company Identification No:- L74899DL1978PLC009181

The Board has recommended dividend of Rs 0.50/- per Equity share of Rs 5/- each.

For Jagsonpal Pharmaceuticals Ltd.

Company Secretary



Factory : 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone : 0091-95129-2275952, 2275953
Factory : Plot No. 14, 15, 16, 55, 56, 57, Sector-5, IIE, Pant Nagar, Rudrapur (U.S. Nagar) - 263153 Uttara Khand

Statement of Assets and Liabilities

Rs. In lacs

Rs. In lacs

A	EQUITY AND LIABILITIES	As at	As at	B	ASSETS	As at	As at
		31.03.2014	31.03.2013			31.03.2014	31.03.2013
1	Shareholders' funds			1	Non-current assets		
	(a) Share Capital	1309.90	1309.90		(a) Fixed Assets	5872.74	6064.85
	(b) Reserves and surplus	8548.97	8527.24		(b) Goodwill	3.00	3.00
	Sub-total - Shareholders' funds	9858.87	9837.14		(c) Non-current investments	0.05	0.05
					(d) Deferred tax assets (net)	0.00	0.00
2	Share application money pending allotment	0.00	0.00		(e) Long term loans and advance	618.52	577.91
					(f) Other non-current assets	0.00	0.00
3	Minority interest	0.00	0.00		Sub-total - Non-current assets	6494.31	6645.81
4	Non-current liabilities			2	Current assets		
	(a) Long term borrowings	0.00	32.05		(a) Current investments		
	(b) Deferred tax liabilities (net)	408.39	417.91		(b) Inventories	3058.92	3006.84
	(c) Other long term liabilities	0.00	0.00		(c) Trade receivables	4522.09	4220.16
	(d) Long term provisions	0.00	0.00		(d) Cash and Cash equivalents	1260.42	1034.34
	Sub-total - Non-current liabilities	408.39	449.96		(e) Short term loans and advance	289.98	392.99
					(f) Other current assets	0.00	0.00
5	Current liabilities				Sub-Total - Current assets	9131.41	8654.33
	(a) Short term borrowing	3595.76	3308.65				
	(b) Trade payables	508.45	650.52		TOTAL - ASSETS	15625.72	15300.14
	(c) Other current liabilities	548.10	399.34				
	(d) Short term provisions	706.15	654.53				
	Sub-Total - Current liabilities	5358.46	5013.04				
	TOTAL - EQUITY AND LIABILITIES	15625.72	15300.14				



For Jagsonpal Pharmaceuticals Limited

Ranvir Singh
Director

**Auditor's Report on Quarterly/Yearly Financial Results for 31.03.2014 of Jagsonpal
Pharmaceuticals Limited Pursuant to the Clause 41 of the Listing Agreement**

To

Board of Directors of Jagsonpal Pharmaceuticals Limited

We have audited the quarterly financial results of Jagsonpal Pharmaceuticals Limited for the quarter ended 31.03.2014 and the year to date results for the period 01.04.2013 to 31.03.2014, attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Companies (Accounting Standards) Rules, 2006 as per section 211(3C) of the Companies Act, 1956 or by the Institute of Chartered Accountants of India and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 31.03.2014 as well as the year to date results for the period from 01.04.2013 to 31.03.2014

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of

shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For P.P.Thukral & Company
Chartered Accountants

Place: New Delhi

Date: 30th May, 2014




Suresh Sethi

Partner

FRN. 000632N

M.No. 89318